Revenue
2014
2022
2023
2024
2025
Protara Therapeutics, Inc. (TARA)
Price$3.05Cached quote
Net income
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | $2.9M | — | — |
| Research & development | $42.6M | $31.7M | $25.0M | $16.8M | $21.1M | $12.0M | $3.9M | $11.8M | $21.7M | $18.9M | $12.4M | $6.4M | $4.0M | $5.9M |
| Operating expenses | $64.5M | $49.2M | $43.6M | $67.1M | $47.5M | $34.4M | $7.8M | $21.4M | $30.4M | $28.7M | $20.9M | $10.5M | $7.1M | $8.0M |
| Operating income | −$64.5M | −$49.2M | −$43.6M | −$67.1M | −$47.5M | −$34.4M | −$7.8M | −$21.4M | −$30.4M | −$28.7M | −$20.9M | −$7.6M | −$7.1M | −$8.0M |
| Operating margin | — | — | — | — | — | — | — | — | — | — | — | −257.12% | — | — |
| EBITDA | −$64.2M | −$48.8M | −$43.3M | −$66.8M | −$47.4M | −$34.3M | −$7.8M | −$21.3M | −$30.2M | −$28.6M | −$20.8M | −$7.5M | −$7.1M | −$7.9M |
| EBITDA margin | — | — | — | — | — | — | — | — | — | — | — | −256.11% | — | — |
| Net income | −$57.4M | −$44.6M | −$40.4M | −$66.0M | −$47.3M | −$34.0M | −$7.8M | −$20.7M | −$30.0M | −$28.5M | −$21.4M | −$3.3M | −$7.9M | −$8.0M |
| Net profit margin | — | — | — | — | — | — | — | — | — | — | — | −113.36% | — | — |
| Basic EPSper basic share | -$1.34 | -$2.17 | -$3.57 | -$5.86 | -$4.21 | -$4.70 | -$3.04 | -$45.80 | -$85.20 | -$68.80 | -$52.00 | -$126.40 | -$2,386.40 | -$2,446.40 |
| Diluted EPSper diluted share | -$1.34 | -$2.17 | -$3.57 | -$5.86 | -$4.21 | -$4.70 | -$3.04 | -$45.80 | -$85.20 | -$68.80 | -$52.00 | -$126.40 | -$2,386.40 | -$2,446.40 |
Owners
Reported shareholders
7.95%of listed shares
Jupiter Topco LLC4.7M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Jupiter Topco LLC | 7.95%4.7M shares |
BlackRock, Inc. | 6.20%3.66M shares |
MILLENNIUM MANAGEMENT LLC | 5.25%3.1M shares |
Velan Capital Investment Management LP | 4.81%2.84M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.89%2.3M shares |
Blackstone Inc. | 3.83%2.27M shares |
ORBIMED ADVISORS LLC | 3.76%2.22M shares |
Opaleye Management Inc. | ≈3.37%1.99M shares |
Sio Capital Management, LLC | 3.25%1.92M shares |
ACORN CAPITAL ADVISORS, LLC | 2.97%1.75M shares |
Integral Health Asset Management, LLC | 2.54%1.5M shares |
5AM Venture Management, LLC | 2.32%1.37M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.24%1.33M shares |
CITADEL ADVISORS LLC | 2.09%1.23M shares |
STATE STREET CORP | 1.81%1.07M shares |
Qube Research & Technologies Ltd | 1.77%1.05M shares |
Balyasny Asset Management L.P. | 1.74%1.03M shares |
Shefferman Jesse | ≈1.73%1.02M shares |
BAKER BROS. ADVISORS LP | 1.64%971.61K shares |
ADAR1 Capital Management, LLC | 1.59%940.51K shares |
Percentages use 59.08M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 8, 2026Form 4 | Zummo JacquelineChief R&D Officer | SellCommon Stock | 1.1K | $5.40 | $6.1K | 94.8K |
| Apr 1, 2026Form 4 | Zummo JacquelineChief R&D Officer | SellCommon Stock | 22.6K | $5.26 | $118.9K | 96.0K |
| May 14, 2025Form 4/A | Levy Richard SDirector | BuyCommon Stock | 20.0K | $3.19 | $63.8K | 51.0K |
| May 14, 2025Form 4 | Levy Richard SDirector | BuyCommon Stock | 20.0K | $3.19 | $63.8K | 51.0K |
| Mar 26, 2025Form 4 · 10b5-1 | Zummo JacquelineChf Scientific Operations Off | SellCommon Stock | 21.2K | $4.53 | $96.1K | 98.9K |